Compare Baxter International Inc (BAX) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Impinj Inc — how do they compare? Baxter International Inc trades at $27.61 (market cap $14.36B), while Impinj Inc trades at $175.27 (market cap $5.38B). The key difference: Baxter International Inc is far larger — about 2.7× Impinj Inc's market cap, and Baxter International Inc pays a 0.14% dividend while Impinj Inc pays none. Which is the better fit depends on your goals.
| BAX | PI | |
|---|---|---|
Market Cap | $14.36B | $5.38B |
Sector | Health | Technology |
52-Week High | $28.35 | $241.91 |
52-Week Low | $15.80 | $91.34 |
Enterprise Value | $21.88B | $5.52B |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.
The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.
Impinj (PI) trades at $183.36, up 6.66% in 24 hours, showing strong momentum after Q2 2026 earnings beat with record revenue and EPS of $0.86 versus $0.81 expected. Technical indicators signal bullish momentum with the stock above key moving averages, though RSI levels suggest overbought conditions. The company maintains solid gross margins of 52.86% but faces profitability challenges with negative net income margins and ROE.
While analyst consensus remains strongly bullish with a $186 price target and institutional buying interest, investors should weigh the stock's premium valuation (P/S 14.26) against ongoing profitability concerns and recent insider selling activity. The company's specialized RAIN RFID technology positions it for growth in retail and supply chain markets, but execution risks and competitive pressures remain key considerations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
